-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
AME started 2026 with a strong beat, posting adjusted EPS of $1.97, $0.07 above consensus. Total sales hit $1.93B, reflecting 11% growth driven by organic gains and M&A contributions. Adjusted operating margins expanded 50 bps to 26.8% on pricing realization and operational execution. Demand trends were clearly positive during Q1, with orders up 23%, resulting in a record backlog. In our view, this enhanced visibility into future revenue and informs our growth assumptions. Amid stronger demand, AME raised full-year 2026 adjusted EPS guidance to $7.94-$8.14 per share, representing 7-10% growth from the prior range of $7.87-$8.07. Both segments participated in Q1 expansion. The EIG segment generated $1.26B in sales (up 11%), benefiting from broad-based orders growth and recent acquisitions. Meanwhile, EMG sales hit $663.9M (up 13%), with operating margins jumping to 25.7% (up 380 bps), driven by organic growth and operational leverage.